According to Barclays, there’s a worldwide opportunity to invest in a corner of healthcare that’s each “significant and underrated.” The segment is clinical nutrition, which the bank has defined as an area focused on patients who need specific complementary nutrition due to chronic health conditions or because they’re unable to eat. Barclays pointed to several drivers of growth: “The rise in chronic disease, an aging population and continued pressure on healthcare spending should proceed to support the expansion of this industry.” “Clinical nutrition provides supplemental nutrition for the undernourished and is a major and underappreciated opportunity currently price roughly $19 billion, driven by strong underlying aspects akin to an aging population, malnutrition and a growing emphasis on self-care,” the bank said in an April 12 memo. . It expects the market to grow to $28 billion by 2030, with China’s market share rising from 20% to 25%. He predicts that the Chinese market in particular may move towards enteral nutrition – also often called tube feeding – and that its market share will increase from 20% today to 46% by 2030. Stock Pick Swiss food and beverage giant Nestle is at its best will give you the chance to profit from this shift towards enteral nutrition given its “innovation leadership” and “consistent advantage” in clinical nutrition, Barclays said. The bank said that for Nestle, this alteration can be a catalyst for more growth in China because the market develops. Barclays said French food company Danone’s medical nutrition business was a “hidden gem”, even though it added that the brand new management had an obligation to “unleash its full potential”. It noted that this unit accounts for a “significant” 12% of group sales and 18% of profits before interest and taxes. “We see this as a ‘hidden gem’ where we expect increased investment from the brand new management team,” Barclays said. “With Danone’s large Specialized Nutrition division is so focused on trends in Chinese infant formula, we consider it’s missing the indisputable fact that 40% of this division is medical and adult nutrition,” Barclays analysts wrote. “We see medical nutrition as a natural hedge against Chinese infant formula, which has been affected by declining birth rates for a few years.” German healthcare company Fresenius can be a “clear beneficiary” of the transition to enteral nutrition because it looks to construct on its leadership position in China in this area, the bank said. The bank said Fresenius was “unique in the market” since it is the one major player energetic in enteral and parenteral nutrition, allowing it to leverage its strength in each areas in addition to capture a bigger available market, the bank said. Parenteral nutrition is delivered by injection when the digestive system will not be functioning properly. Regarding China, Barclays said: “Fresenius SE has the most important market share, which is 80% parenteral, putting it in a robust position to profit from faster growth than the remaining of the world. It also has a robust position in the market of enteric drugs. in the region, positioning it to profit from its high growth potential.” — Michael Bloom of CNBC contributed to this report.